Neurocrine Biosciences (NBIX) Revenue: 2010-2021
Historic Revenue for Neurocrine Biosciences (NBIX) over the last 9 years, with Sep 2021 value amounting to $296.0 million.
- Neurocrine Biosciences' Revenue rose 14.51% to $296.0 million in Q3 2021 from the same period last year, while for Sep 2021 it was $1.1 billion, marking a year-over-year increase of 2.62%. This contributed to the annual value of $1.0 billion for FY2020, which is 32.71% up from last year.
- Latest data reveals that Neurocrine Biosciences reported Revenue of $296.0 million as of Q3 2021, which was up 2.46% from $288.9 million recorded in Q2 2021.
- Neurocrine Biosciences' Revenue's 5-year high stood at $302.4 million during Q2 2020, with a 5-year trough of $6.3 million in Q2 2017.
- In the last 3 years, Neurocrine Biosciences' Revenue had a median value of $244.1 million in 2019 and averaged $241.4 million.
- In the last 5 years, Neurocrine Biosciences' Revenue soared by 1,429.68% in 2018 and then decreased by 4.46% in 2021.
- Quarterly analysis of 5 years shows Neurocrine Biosciences' Revenue stood at $94.5 million in 2017, then surged by 39.12% to $131.5 million in 2018, then soared by 85.64% to $244.1 million in 2019, then grew by 1.56% to $247.9 million in 2020, then increased by 14.51% to $296.0 million in 2021.
- Its Revenue was $296.0 million in Q3 2021, compared to $288.9 million in Q2 2021 and $236.6 million in Q1 2021.